Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study

We hypothesized that sorafenib plus transarterial chemoembolization (TACE) would confer survival benefits over sorafenib alone for advanced hepatocellular carcinoma (aHCC). We investigated this while using the population-based All-Cancer Dataset to assemble a cohort (n = 3674; median age, 60; 83% me...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Victor C., Chen, Yu-Ching, Chen, Yang-Yuan, Su, Yu-Chieh, Ku, Ming-Chang, Kuo, Jung-Tsung, Yoshida, Go J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679028/
https://www.ncbi.nlm.nih.gov/pubmed/31311148
http://dx.doi.org/10.3390/cancers11070985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679028/
https://www.ncbi.nlm.nih.gov/pubmed/31311148
http://dx.doi.org/10.3390/cancers11070985

Ejemplares similares